Pieris Pharmaceuticals (NASDAQ:PIRS) Posts Earnings Results, Beats Estimates By $0.05 EPS

Pieris Pharmaceuticals (NASDAQ:PIRSGet Rating) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.05, MarketWatch Earnings reports. Pieris Pharmaceuticals had a negative return on equity of 97.46% and a negative net margin of 147.01%. During the same period last year, the business posted ($0.07) EPS.

Shares of NASDAQ:PIRS traded down $0.12 during trading on Thursday, reaching $1.67. 1,023,370 shares of the company traded hands, compared to its average volume of 564,896. The company’s 50 day moving average is $2.97 and its two-hundred day moving average is $3.37. The firm has a market capitalization of $123.75 million, a PE ratio of -2.36 and a beta of 1.19. Pieris Pharmaceuticals has a 52 week low of $1.61 and a 52 week high of $6.15.

Several large investors have recently added to or reduced their stakes in PIRS. Oppenheimer & Co. Inc. bought a new stake in shares of Pieris Pharmaceuticals during the 1st quarter valued at $32,000. Royal Bank of Canada increased its stake in shares of Pieris Pharmaceuticals by 226.0% in the second quarter. Royal Bank of Canada now owns 12,975 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 8,995 shares during the period. LPL Financial LLC acquired a new stake in shares of Pieris Pharmaceuticals in the third quarter valued at about $84,000. Charles Schwab Investment Management Inc. increased its stake in shares of Pieris Pharmaceuticals by 83.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 35,732 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 16,295 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in shares of Pieris Pharmaceuticals by 149.9% in the first quarter. JPMorgan Chase & Co. now owns 63,643 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 38,179 shares during the period. Hedge funds and other institutional investors own 65.30% of the company’s stock.

Separately, StockNews.com started coverage on Pieris Pharmaceuticals in a report on Thursday, March 31st. They issued a “hold” rating on the stock.

About Pieris Pharmaceuticals (Get Rating)

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids.

See Also

Earnings History for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.